A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

1期 已完成 NCT06440980

摘要

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.

Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7

Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days) · Nanogram* hours/milliliter (ng*h/ml)

Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7

Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days) · Nanogram per milliliter (ng/ml)

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Ignite Pilot: Goal Setting in a Digital Weight Loss Intervention — Stanford University
• Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects — University of Pennsylvania
• Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
• Time Restricted Eating for Weight Loss Maintenance — NYU Langone Health
• Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Effect of PDE5 Inhibition on Adipose Metabolism in Humans — Vanderbilt University Medical Center

全部试验